title: [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
abstract: GLP-1 receptors agonists have been a substantial change in treatment of type 2 diabetes mellitus, and its weekly administration has broken pre-established schemes. Daily exenatide is administered every 12 hours (BID) subcutaneously, while weekly exenatide is administered once a week. Both molecules share a common mechanism of action but have differential effects on basal and postprandial glucose. We review the major clinical trials with both exenatide BID and weekly exenatide. It can be concluded that exenatide BID shows a hypoglycemic effect similar to other treatments for type 2 DM but adding significant weight loss with low incidence of hypoglycemia. Weekly exenatide decreases HbA1c similar to liraglutide but larger than exenatide BID, both glargine and biphasic insulin, sitagliptin, and pioglitazone, maintaining weight loss and adding to gastrointestinal intolerance the induration at the injection site as a side effect.
authors.affiliation: Servicio de Endocrinología y Nutrición, Unidad de Obesidad, Hospital Universitari Arnau de Vilanova, Lleida, España. Electronic address: alecube@gmail.com.
authors.forename: Albert
authors.initials: A
authors.lastname: Lecube
authors.affiliation: Servicio de Endocrinología y Nutrición, Unidad de Obesidad, Hospital Universitari Arnau de Vilanova, Lleida, España.
authors.forename: Marta
authors.initials: M
authors.lastname: Bueno
authors.affiliation: Servicio de Endocrinología y Nutrición, Unidad de Obesidad, Hospital Universitari Arnau de Vilanova, Lleida, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Suárez
mesh_terms: D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004339:Drug Compounding; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D054795:Incretins / Q000008:administration & dosage* / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D010455:Peptides / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D014688:Venoms / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D054795:Incretins; D010455:Peptides; D014688:Venoms; D000077270:Exenatide
keywords: AMIGO; DURATION; Diabetes mellitus; Exenatida diaria; Exenatida semanal; Exenatide; Exendin-4; Exendina-4; GLP-1; Glucemia posprandial; Incretinas; Incretins; Postprandial glucose; Semanal; Weekly; Weekly exenatide